Stage IV Melanoma Completed Phase 2 Trials for Pazopanib (DB06589)

IndicationStatusPhase
DBCOND0028660 (Stage IV Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01107665Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV MelanomaTreatment